Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids

Vanessa Shih, Erika Banks, Nicole G. Bonine, Amanda Harrington, Dana Stafkey-Mailey, Binglin Yue, Jiatao Michael Ye, Rupali M. Fuldeore, Patrick Gillard

Research output: Contribution to journalArticle

Abstract

Objective: To perform a retrospective, matched-cohort, longitudinal evaluation of annual pre- and post-diagnosis costs incurred among women with uterine fibroids (UF) (cases) compared to controls without UF. Methods: Data were derived from the IBM Watson Health MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 18–64 years with ≥1 inpatient or outpatient medical claim with an initial UF diagnosis (index date) from 1 January 2010 to 31 December 2014 were included. Healthcare resource utilization (HCRU) data including pharmacy, outpatient and inpatient hospital claims were collected for 1 year pre-index and ≤5 years post-index. All-cause costs (adjusted to 2017 $US) were compared between cases and controls using multivariable regression models. Results: Analysis included 205,098 (Commercial) and 24,755 (Medicaid) case–control pairs. HCRU and total all-cause healthcare costs were higher for cases versus controls during the pre-index year and all years post-index. Total unadjusted mean all-cause costs were $1197 higher (p <.0001; Commercial) and $2813 higher (standardized difference 0.08; Medicaid) for cases during the pre-index year. Total adjusted mean all-cause costs in the first year post-index were $14,917 for cases versus $5717 for controls in the Commercial population, and $20,244 versus $10,544, respectively, in the Medicaid population. In Years 2–5 post-index, incremental mean adjusted total costs decreased, but remained significantly higher for cases versus controls at all time points in both populations (all p <.05). Conclusions: Costs were higher for women with UF compared to women without UF during the pre-index year and over 5 years post-index; differences were greatest in the first year post-index.

Original languageEnglish (US)
JournalCurrent Medical Research and Opinion
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Leiomyoma
Medicaid
Delivery of Health Care
Costs and Cost Analysis
Inpatients
Outpatients
Population
Health Care Costs
Databases
Health

Keywords

  • Cost
  • economic burden
  • healthcare resource utilization
  • leiomyomata
  • uterine fibroids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids. / Shih, Vanessa; Banks, Erika; Bonine, Nicole G.; Harrington, Amanda; Stafkey-Mailey, Dana; Yue, Binglin; Ye, Jiatao Michael; Fuldeore, Rupali M.; Gillard, Patrick.

In: Current Medical Research and Opinion, 01.01.2019.

Research output: Contribution to journalArticle

Shih, Vanessa ; Banks, Erika ; Bonine, Nicole G. ; Harrington, Amanda ; Stafkey-Mailey, Dana ; Yue, Binglin ; Ye, Jiatao Michael ; Fuldeore, Rupali M. ; Gillard, Patrick. / Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids. In: Current Medical Research and Opinion. 2019.
@article{3b3a8c632a674c57956968be86f5dcfe,
title = "Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids",
abstract = "Objective: To perform a retrospective, matched-cohort, longitudinal evaluation of annual pre- and post-diagnosis costs incurred among women with uterine fibroids (UF) (cases) compared to controls without UF. Methods: Data were derived from the IBM Watson Health MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 18–64 years with ≥1 inpatient or outpatient medical claim with an initial UF diagnosis (index date) from 1 January 2010 to 31 December 2014 were included. Healthcare resource utilization (HCRU) data including pharmacy, outpatient and inpatient hospital claims were collected for 1 year pre-index and ≤5 years post-index. All-cause costs (adjusted to 2017 $US) were compared between cases and controls using multivariable regression models. Results: Analysis included 205,098 (Commercial) and 24,755 (Medicaid) case–control pairs. HCRU and total all-cause healthcare costs were higher for cases versus controls during the pre-index year and all years post-index. Total unadjusted mean all-cause costs were $1197 higher (p <.0001; Commercial) and $2813 higher (standardized difference 0.08; Medicaid) for cases during the pre-index year. Total adjusted mean all-cause costs in the first year post-index were $14,917 for cases versus $5717 for controls in the Commercial population, and $20,244 versus $10,544, respectively, in the Medicaid population. In Years 2–5 post-index, incremental mean adjusted total costs decreased, but remained significantly higher for cases versus controls at all time points in both populations (all p <.05). Conclusions: Costs were higher for women with UF compared to women without UF during the pre-index year and over 5 years post-index; differences were greatest in the first year post-index.",
keywords = "Cost, economic burden, healthcare resource utilization, leiomyomata, uterine fibroids",
author = "Vanessa Shih and Erika Banks and Bonine, {Nicole G.} and Amanda Harrington and Dana Stafkey-Mailey and Binglin Yue and Ye, {Jiatao Michael} and Fuldeore, {Rupali M.} and Patrick Gillard",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/03007995.2019.1642186",
language = "English (US)",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids

AU - Shih, Vanessa

AU - Banks, Erika

AU - Bonine, Nicole G.

AU - Harrington, Amanda

AU - Stafkey-Mailey, Dana

AU - Yue, Binglin

AU - Ye, Jiatao Michael

AU - Fuldeore, Rupali M.

AU - Gillard, Patrick

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To perform a retrospective, matched-cohort, longitudinal evaluation of annual pre- and post-diagnosis costs incurred among women with uterine fibroids (UF) (cases) compared to controls without UF. Methods: Data were derived from the IBM Watson Health MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 18–64 years with ≥1 inpatient or outpatient medical claim with an initial UF diagnosis (index date) from 1 January 2010 to 31 December 2014 were included. Healthcare resource utilization (HCRU) data including pharmacy, outpatient and inpatient hospital claims were collected for 1 year pre-index and ≤5 years post-index. All-cause costs (adjusted to 2017 $US) were compared between cases and controls using multivariable regression models. Results: Analysis included 205,098 (Commercial) and 24,755 (Medicaid) case–control pairs. HCRU and total all-cause healthcare costs were higher for cases versus controls during the pre-index year and all years post-index. Total unadjusted mean all-cause costs were $1197 higher (p <.0001; Commercial) and $2813 higher (standardized difference 0.08; Medicaid) for cases during the pre-index year. Total adjusted mean all-cause costs in the first year post-index were $14,917 for cases versus $5717 for controls in the Commercial population, and $20,244 versus $10,544, respectively, in the Medicaid population. In Years 2–5 post-index, incremental mean adjusted total costs decreased, but remained significantly higher for cases versus controls at all time points in both populations (all p <.05). Conclusions: Costs were higher for women with UF compared to women without UF during the pre-index year and over 5 years post-index; differences were greatest in the first year post-index.

AB - Objective: To perform a retrospective, matched-cohort, longitudinal evaluation of annual pre- and post-diagnosis costs incurred among women with uterine fibroids (UF) (cases) compared to controls without UF. Methods: Data were derived from the IBM Watson Health MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 18–64 years with ≥1 inpatient or outpatient medical claim with an initial UF diagnosis (index date) from 1 January 2010 to 31 December 2014 were included. Healthcare resource utilization (HCRU) data including pharmacy, outpatient and inpatient hospital claims were collected for 1 year pre-index and ≤5 years post-index. All-cause costs (adjusted to 2017 $US) were compared between cases and controls using multivariable regression models. Results: Analysis included 205,098 (Commercial) and 24,755 (Medicaid) case–control pairs. HCRU and total all-cause healthcare costs were higher for cases versus controls during the pre-index year and all years post-index. Total unadjusted mean all-cause costs were $1197 higher (p <.0001; Commercial) and $2813 higher (standardized difference 0.08; Medicaid) for cases during the pre-index year. Total adjusted mean all-cause costs in the first year post-index were $14,917 for cases versus $5717 for controls in the Commercial population, and $20,244 versus $10,544, respectively, in the Medicaid population. In Years 2–5 post-index, incremental mean adjusted total costs decreased, but remained significantly higher for cases versus controls at all time points in both populations (all p <.05). Conclusions: Costs were higher for women with UF compared to women without UF during the pre-index year and over 5 years post-index; differences were greatest in the first year post-index.

KW - Cost

KW - economic burden

KW - healthcare resource utilization

KW - leiomyomata

KW - uterine fibroids

UR - http://www.scopus.com/inward/record.url?scp=85071323623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071323623&partnerID=8YFLogxK

U2 - 10.1080/03007995.2019.1642186

DO - 10.1080/03007995.2019.1642186

M3 - Article

C2 - 31290716

AN - SCOPUS:85071323623

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

ER -